BR112022013468A2 - Proteínas rspo1 e seu uso - Google Patents

Proteínas rspo1 e seu uso

Info

Publication number
BR112022013468A2
BR112022013468A2 BR112022013468A BR112022013468A BR112022013468A2 BR 112022013468 A2 BR112022013468 A2 BR 112022013468A2 BR 112022013468 A BR112022013468 A BR 112022013468A BR 112022013468 A BR112022013468 A BR 112022013468A BR 112022013468 A2 BR112022013468 A2 BR 112022013468A2
Authority
BR
Brazil
Prior art keywords
rspo1
diabetes
protein
beta cells
beta cell
Prior art date
Application number
BR112022013468A
Other languages
English (en)
Portuguese (pt)
Inventor
COLLOMBAT Patrick
SILVANO Serena
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Univ Cote D'azur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Cote D'azur filed Critical Inst Nat Sante Rech Med
Publication of BR112022013468A2 publication Critical patent/BR112022013468A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112022013468A 2020-01-10 2021-01-08 Proteínas rspo1 e seu uso BR112022013468A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305016 2020-01-10
PCT/EP2021/050289 WO2021140209A1 (en) 2020-01-10 2021-01-08 Rspo1 proteins and their use

Publications (1)

Publication Number Publication Date
BR112022013468A2 true BR112022013468A2 (pt) 2022-09-13

Family

ID=69185555

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013468A BR112022013468A2 (pt) 2020-01-10 2021-01-08 Proteínas rspo1 e seu uso

Country Status (10)

Country Link
US (1) US20230241161A1 (cg-RX-API-DMAC10.html)
EP (1) EP4087863A1 (cg-RX-API-DMAC10.html)
JP (2) JP7767289B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220152202A (cg-RX-API-DMAC10.html)
CN (1) CN114929731A (cg-RX-API-DMAC10.html)
AU (1) AU2021205639A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022013468A2 (cg-RX-API-DMAC10.html)
CA (1) CA3163861A1 (cg-RX-API-DMAC10.html)
IL (1) IL294571A (cg-RX-API-DMAC10.html)
WO (1) WO2021140209A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024210262A1 (en) * 2023-01-19 2025-07-10 Centre National De La Recherche Scientifique Recombinant variants of r-spondin proteins and their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
HUE027179T2 (en) 2006-10-20 2016-10-28 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Angiogenesis and vasculogenesis modulator for Rspond
WO2008088524A2 (en) * 2006-12-28 2008-07-24 Nuvelo, Inc. Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
ES2769786T3 (es) * 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
WO2014059068A1 (en) * 2012-10-11 2014-04-17 The Trustees Of The University Of Pennsylvania Methods for the treatment and prevention of osteoporosis and bone-related disorders
WO2016193497A1 (en) * 2015-06-04 2016-12-08 Ospedale San Raffaele Srl Inhibitor of igfbp3/tmem219 axis and diabetes
JP2021020900A (ja) 2019-07-29 2021-02-18 国立大学法人北海道大学 糖代謝異常改善剤
IL310154A (en) * 2021-07-15 2024-03-01 Diogenx Recombinant variants of r-spondin proteins and their use

Also Published As

Publication number Publication date
AU2021205639A1 (en) 2022-07-14
KR20220152202A (ko) 2022-11-15
CN114929731A (zh) 2022-08-19
IL294571A (en) 2022-09-01
JP2023509189A (ja) 2023-03-07
JP7767289B2 (ja) 2025-11-11
EP4087863A1 (en) 2022-11-16
US20230241161A1 (en) 2023-08-03
WO2021140209A1 (en) 2021-07-15
CA3163861A1 (en) 2021-07-15
JP2026021430A (ja) 2026-02-10

Similar Documents

Publication Publication Date Title
Fries et al. Combining xenon and mild therapeutic hypothermia preserves neurological function after prolonged cardiac arrest in pigs
ES2653615T3 (es) Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos
Park et al. Hypopigmentation and subcutaneous fat, muscle atrophy after local corticosteroid injection
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
ES2723887T3 (es) Formulación de relación fija de insulina glargina/lixisenatida
Ghasemi et al. Iatrogenic botulism after the therapeutic use of botulinum toxin-A: a case report and review of the literature
Colangelo et al. Polydeoxyribonucleotide regulation of inflammation
BR112015010203A8 (pt) composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina
KR20140047043A (ko) PTH, PTHrP를 위한 약물 전달 방법 및 관련 펩티드
AR099078A2 (es) Un medicamento que comprende acetato de glatiramer
BR112015025072A2 (pt) novo derivado de ácido 3-(4-(benziloxi)fenil)hex-4-inóico, método de preparação do mesmo e composição farmacêutica para prevenção e tratamento de doenças metabólicas incluindo o mesmo como ingrediente eficaz
Barreto et al. Platelet-rich plasma and corticosteroid in the treatment of rotator cuff impingement syndrome: randomized clinical trial
BRPI0309689A2 (pt) formulação de uma mistura de flavonóides de anel-b-livre e flavanos como agente terapêutico.
Chang et al. The effectiveness of platelet-rich plasma and radial extracorporeal shock wave compared with platelet-rich plasma in the treatment of moderate carpal tunnel syndrome
Courseau et al. Efficacy of intra-articular botulinum toxin in osteoarticular joint pain: a meta-analysis of randomized controlled trials
BR112019009511A2 (pt) polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.
Cho et al. Complex regional pain syndrome type 1 relieved by acupuncture point injections with placental extract
EP1846022B1 (en) Methods for treating adhesive capsulitis
Pandey et al. Recent developments in diabetes management: Exploring receptors, pathways, and compounds
BR112022014119A2 (pt) Administração oral de peptídeos
Velasco-Montes et al. Rabdomiólisis secundaria a tratamiento con quetiapina.
Chen et al. Icariin inhibits apoptosis in OGD-induced neurons by regulating M2 pyruvate kinase
Kersschot Intra-articular Glucose Injections for Orthoregeneration of Frozen Shoulder. A Clinical Case.